IBMFS and risks/surveillance impacting HCT timing
| Disorder . | MDS/AML risk . | Solid tumor risk . | Other surveillance . |
|---|---|---|---|
| Fanconi anemia | + | + | |
| Dyskeratosis congenita/ telomere diseases | + | + | Immune deficiency Liver disease Lung disease |
| Shwachman-Diamond syndrome | + | +/– | Immune deficiency |
| Diamond Blackfan anemia | +/– | +/– | Iron overload |
| GATA2 deficiency | + | Immune deficiency | |
| SAMD9/SAMD9L syndromes | + | Immune deficiency | |
| RUNX1 | + | ||
| ANKRD26 | + | ||
| ERCC6L2 | + | ||
| MECOM | + | ||
| DDX41 | + |
| Disorder . | MDS/AML risk . | Solid tumor risk . | Other surveillance . |
|---|---|---|---|
| Fanconi anemia | + | + | |
| Dyskeratosis congenita/ telomere diseases | + | + | Immune deficiency Liver disease Lung disease |
| Shwachman-Diamond syndrome | + | +/– | Immune deficiency |
| Diamond Blackfan anemia | +/– | +/– | Iron overload |
| GATA2 deficiency | + | Immune deficiency | |
| SAMD9/SAMD9L syndromes | + | Immune deficiency | |
| RUNX1 | + | ||
| ANKRD26 | + | ||
| ERCC6L2 | + | ||
| MECOM | + | ||
| DDX41 | + |